Test ID APBCC Adaptor Protein 3 Beta2 (AP3B2) Antibody, Cell-Binding Assay, Spinal Fluid
Specimen Required
Only orderable as a part of a profile. For more information see MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
Container/Tube: Sterile vial
Preferred: Vial number 1
Acceptable: Any vial
Specimen Volume: 1.5 mL
Secondary ID
615860Useful For
The differential diagnosis of patients presenting with mixed cerebellar and sensory ataxia and myeloneuropathy
Evaluating AP3B2 (adaptor protein 3 beta2)-IgG by cell-binding assay using spinal fluid specimens
Testing Algorithm
If the indirect immunofluorescence (IFA) pattern suggests AP3B2 (adaptor protein 3 beta2), then this test and AP3B2 antibody IFA titer will be performed at an additional charge.
Method Name
Only orderable as part of a profile. For more information see MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
Cell-Binding Assay (CBA)
Reporting Name
AP3B2 CBA, CSFSpecimen Type
CSFSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
Specimen Type | Temperature | Time | |
---|---|---|---|
CSF | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Clinical Information
AP3B2 (adaptor protein 3 beta2)-IgG is a marker of an autoimmune disorder unified by gait instability as the predominant neurologic presentation. Patients present with either cerebellar, dorsal column, or sensory neuronal dysfunction. Clinical improvement following treatment has been reported. AP3B2 autoimmunity appears rare, is accompanied by ataxia (sensory or cerebellar), and is potentially treatable.
Reference Values
Only orderable as a part of a profile. For more information see MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
Negative
Cautions
A negative result does not exclude neurological autoimmunity or cancer.
Day(s) Performed
5 days if negative/10 days if positive
Report Available
5 to 10 daysPerforming Laboratory

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86255